Skip to content

Gerandomiseerde vergelijking tussen indocyanine groen en indocyanine groen gekoppeld aan humaan serum albumine bij intra-operatieve fluorescente beeldvorming van schildwachtklieren bij baarmoederhalskankerpatienten.

Randomized comparison of indocyanine green (ICG) adsorbed to albumin (ICG:HSA) versus ICG alone for sentinel lymph node mapping in cervical cancer patients.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23689
Enrollment
18
Registered
2011-04-27
Start date
2011-04-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Standard lymphadenectomy will be performed. Before median laparotomy, the near-infrared dye ICG:HSA of ICG alone will be injected peritumorally around the cervix and lymphatic pathways and lymph nodes

Sponsors

Leiden University Medical Center (LUMC)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cervical cancer patients planned to undergo a lymphadenectomy.

Exclusion criteria

Exclusion criteria: 1. History of allergy to iodine, shellfish, indocyanine green or human serum albumin; 2. Pregnancy; 3. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.

Design outcomes

Primary

MeasureTime frame
Signal-to-background ratio of identified SLNs, defined as the fluorescence intensity of SLN divided by the fluorescence intensity of the surrounding background.

Secondary

MeasureTime frame
1. Number of identified SLNs: fluorescence and non-fluorescence; 2. In vivo and ex vivo fluorescence intensity of SLNs; 3. Identification ratio; 4. Percutaneous lymphatic channel identification; 5. Time to identification of SLN.

Contacts

Public ContactC.J.H. Velde, van de

Leiden University Medical Center (LUMC), Department of Surgical Oncology, P.O. Box 9600

c.j.h.van_de_velde@lumc.nl+31 (0)71 5262309

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)